BMY
Bristol Myers Squibb CoPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Growth Portfolio revenues | $6.2B | first quarter of 2026 | — |
|
|
|||
| Legacy Portfolio revenues | $5.3B | first quarter of 2026 | — |
|
|
|||
| Brianze growth | 53% | Q1 2026 call | — |
| Cabenphi revenue | $56M | Q1 2026 call | — |
| CITIC2 growth | 20% | Q1 2026 call | — |
| growth portfolio global revenue | $6.2B | Q1 2026 call | — |
| growth portfolio sales | 9% | Q1 2026 call | — |
| Kamsaya's revenue | $314M | Q1 2026 call | — |
| Kvantik revenue | $163M | Q1 2026 call | — |
| operating cash flow non-GAAP | $1.1B | Q1 2026 call | — |
| Rebezel growth | 15% | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BMY
this stock
Bristol Myers Squibb Co
|
$118.32B | +7.9% | -0.2% | 16.2 | 1.9% |
|
LLY
ELI LILLY & Co
|
$1.15T | +13.3% | +44.7% | 43.2 | 1.0% |
|
JNJ
Johnson & Johnson
|
$623.71B | +28.0% | +6.0% | 30.0 | 1.1% |
|
ABBV
AbbVie Inc.
|
$441.54B | +11.5% | +8.6% | 123.1 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$308.98B | +21.4% | +1.4% | 35.2 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BMY | -0.1% | +3.6% | +2.9% | -0.1% | +7.9% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +0.0% | +2.7% | -4.5% | +0.0% | -1.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.